FDA updates its guidance, potentially enabling broader adoption of LLM-based clinical decision support software in radiology.
Key Details
- 1FDA released updated guidance on regulating clinical decision-support (CDS) software as a medical device in January 2024.
- 2The new guidance clarifies that certain LLM and CDS tools that do not directly analyze images may be exempt from device regulation if they meet four specific criteria.
- 3Previously, tools generating diagnostic text recommendations or risk predictions were typically regulated as medical devices.
- 4The updated interpretation may open opportunities for more LLM-based applications to assist radiologists without requiring full FDA device approval, provided clinicians retain review authority.
- 5Image-analyzing AI (such as CAD or denoising tools) remains regulated as medical devices.
Why It Matters
This policy shift could accelerate development and clinical adoption of text-based AI assistants and reporting tools in radiology, reducing regulatory barriers. Clarity from the FDA also helps innovators and healthcare providers assess which AI-driven software must undergo formal device review.
Source
AuntMinnie
Related News
•HealthExec
FDA Eases Path for AI in Clinical Decision Support and Healthcare Innovation
FDA publishes new guidance to promote innovation in general wellness and clinical decision support, impacting medical AI including radiology.
•AuntMinnie
Citizen Petition Proposes Streamlined FDA Pathway for Radiology AI
A petition urges the FDA to allow certain radiology AI software updates via postmarket study requirements instead of new 510(k) applications.
•Radiology Business
FDA-Cleared Imaging AI Proliferates, But Reimbursement Stalls
Despite a surge in FDA-cleared radiology AI tools, very few qualify for reimbursement due to lack of supporting clinical studies.